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Role of cytochrome P-450 as a source of catalytic iron in
cisplatin-induced nephrotoxicity.
Background. Iron plays a role in free radical-mediated tissue
injury, including cisplatin-induced nephrotoxicity. However, the
source of iron (catalyzing free radical reactions) is not known. We
examined the role of cytochrome P-450 as a source of catalytic
iron in cisplatin-induced nephrotoxicity both in vivo and in vitro.
Methods. Cisplatin-induced acute renal failure was produced in
rats by intraperitoneal injection of cisplatin (10 mg/kg body wt).
Piperonyl butoxide, a cytochrome P-450 inhibitor, was adminis-
tered intraperitoneally (400 mg/kg body wt twice at 48-hr inter-
vals) prior to cisplatin injection. The effects of cisplatin in the
absence or presence of piperonyl butoxide on the belomycin-
detectable iron, cytochrome P-450 content in the kidney, and
renal functional and histological changes were evaluated. In an in
vitro study, the effect of cytochrome P-450 inhibitors, cimetidine
or piperonyl butoxide, on cisplatin-induced cytotoxicity and cata-
lytic iron release from LLC-PK1 cells was examined.
Results. In cisplatin-treated rats, there was a marked decrease in
the cytochrome P-450 content specifically in the kidney, accom-
panied by increased bleomycin-detectable iron content in the
kidney. Piperonyl butoxide prevented cisplatin-induced loss of
cytochrome P-450 as well as the increase of bleomycin-detectable
iron in the kidney, along with both functional and histological
protection. Both cimetidine and piperonyl butoxide prevented
cisplatin-induced increase in bleomycin-detectable iron and cyto-
toxicity in LLC-PK1 cells. Treatment of cimetidine did not affect
cellular uptake of cisplatin.
Conclusion. Cytochrome P-450, a group of heme proteins, may
serve as a significant source of catalytic iron in cisplatin-induced
nephrotoxicity.
A large body of evidence has implicated an important
role of iron in in vivo and in vitro models of reactive oxygen
metabolite-mediated tissue injury [1–10], including cispla-
tin-induced nephrotoxicity [10]. Iron, a transition metal,
can participate in the generation of powerful oxygen me-
tabolites such as hydroxyl radical by the metal-catalyzed
Haber-Weiss reaction and/or in the generation of highly
reactive iron-oxygen complexes such as ferryl or perferryl
ion [1]. Indeed, iron chelators including deferoxamine and
2,3-dihydroxybenzoic acid have been shown to be protec-
tive in several forms of ischemic, toxic and immune-
mediated renal injury [2–7]. The catalytic iron capable of
catalyzing free radical reactions, as measured by the bleo-
mycin assay, has been reported to be increased in ischemia/
reperfusion-induced [8] and myoglobinuric acute renal
failure [9].
Cisplatin is one of the most effective chemotherapeutic
agents, and plays a major role in the treatment of a variety
of human solid tumors [10, 11]. The most common adverse
effect limiting the use of cisplatin is nephrotoxicity that
develops primarily in the S3 segment of the proximal tubule
[12]. Aggressive hydration and forced diuresis have been
utilized to reduce cisplatin-induced nephrotoxicity [13].
The mechanism underlying this nephrotoxicity is not well
understood [14], however, reactive oxygen metabolites have
been implicated [15]. The role of iron in mediating tissue
injury via the generation of hydroxyl radical formation in
this model of renal injury has been examined in our
previous study [10]. In addition, a recent study has demon-
strated that the induction of heme oxygenase provided
marked protection against cisplatin nephrotoxicity [16] by
rapid degradation of the labile heme moiety rendering the
heme iron unavailable to participate in oxidant stress.
Cytochrome P-450 as a potential source of iron was first
described in reperfusion injury of rabbit lung [17] and rat
kidneys [18], as well as in myoglobinuric acute renal failure
[9]. However, the role of cytochrome P-450 in cisplatin-
induced nephrotoxicity has not been previously examined.
If cytochrome P-450 serves as a source of iron then this
should result in the loss of cytochrome P-450. Indeed,
relevant to the current study is the observation that the
cytochrome P-450 content in the kidney was markedly
decreased in cisplatin nephrotoxicity [19]. Therefore, the
present study was designed to test the hypothesis that the
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heme moiety of cytochrome P-450 may serve as a significant
source of catalytic iron in cisplatin-induced nephrotoxicity.
METHODS
In vivo study
Cisplatin-induced acute renal failure. Cisplatin model of
acute renal failure was induced in rats as described by
Capasso et al [20] and in our previous studies [10]. Male
Sprague-Dawley rats weighing 200 to 250 g were allowed
free access to rat chow (Purina) and water. The animals
received intraperitoneal injection of cisplatin (Bristol-My-
ers Squibb Co., Princeton, NJ, USA) at a dose of 10 mg/kg
body wt and were sacrificed at 72 hours after cisplatin
injection. Blood, kidneys, and a piece of liver were obtained
for the various measurements. Renal impairment was as-
sessed by blood urea nitrogen (BUN), plasma creatinine,
and kidney histology. BUN and creatinine were measured
by the use of Sigma diagnostic kits (Sigma Chemical Co.,
St. Louis, MO, USA). Kidney histology was studied as
described below.
Kidney histology. The kidneys were sectioned and a
portion fixed in 10% formalin, dehydrated and embedded
in paraffin. Sections were cut at 2 mm and stained with
periodic acid-Schiff reagent. The slides were coded and
semiquantitative analysis of the kidney sections was per-
formed without knowledge of the treatment protocol as
previously described [10, 21]. The changes seen were
limited to the tubulointerstitial areas and graded as follows:
0 5 normal; I 5 areas of tubular epithelial cell swelling,
vacuolar degeneration, necrosis, and desquamation involv-
ing ,25% of cortical tubules; II 5 similar changes involv-
ing .25% but ,50% of cortical tubules; III 5 similar
changes involving .50% but ,75% of cortical tubules;
IV 5 similar changes involving .75% of cortical tubules.
Bleomycin-detectable iron assay. Catalytic iron content in
the kidney was measured by the bleomycin-detectable iron
assay as detailed in our previous studies [8–10]. Briefly, the
kidney tissue was homogenized in Chelex-treated pyrogen-
free water, loaded into a Centriprep-30 that has a molec-
ular cut-off value of 30 kD, and centrifuged at 1500 g for 30
minutes at 4°C. The resulting clear ultrafiltrate was col-
lected and used for the bleomycin-detectable iron assay. All
reagents except for the sample under test were made up in
Chelex-treated pyrogen-free water in iron-free plastic con-
tainers and shaken with Chelex-100 to remove as much
contaminating iron as possible. The reaction mixture con-
tained in order: 0.5 ml of calf thymus DNA (1 mg/ml), 0.05
ml of bleomycin sulfate (1 mg/ml), 0.1 ml of MgCl2 (50
mM), 0.1 ml of sample, either 0.05 ml of HCl (10 mM)
[8–10] or 0.1 ml of imidazole [10, 22], 0.1 ml of Chelex-
treated pyrogen free water and 0.1 ml of ascorbic acid (8
mM). Sample blank was identical except that bleomycin was
omitted. The samples were mixed and then incubated at
37°C for two hours with shaking. The reaction was stopped
by adding 0.1 ml of 0.1 M EDTA, and mixed with 1 ml
thiobarbituric acid (1% wt/vol in 50 mM NaOH) and 1 ml
HCl (25%, vol/vol). The reaction mixture was then heated
at 100°C for 15 minutes, cooled, and the resulting chromo-
gen measured using spectrophotometer by its absorbance
at 532 nm. A standard curve was prepared using various
concentrations of FeCl3 (0 to 50 mM) in Chelex-treated
pyrogen free water. The amount of bleomycin-detectable
iron in the test sample was calculated from the standard
curve and the results expressed as nmol/mg tissue protein
recovered from the homogenate. Protein concentration was
measured by the use of Bio-Rad reagent (Bio-Rad Labo-
ratories, Hercules, CA, USA).
Determination of cytochrome P-450 content. Fresh kidney
or liver tissue was homogenized in ice-cold isotonic KCl
(0.15 M). The homogenate was then centrifuged at 15,000 g
for 20 minutes at 4°C and the precipitate discarded. The
resulting supernatant was further centrifuged at 105,000 g
for 60 minutes at 4°C to obtain microsomes. The firmly
packed pellet of microsomes was resuspended in 0.1 M
potassium phosphate buffer, pH 7.4, usually at a concen-
tration of 10 mg of protein per ml. Cytochrome P-450
content was measured by the method of Omura and Sato
[23]. In brief, the suspensions of microsomes were diluted
to approximately 1 mg of protein per ml with the assay
buffer containing 0.1 M potassium phosphate buffer, pH
7.25, 20% glycerol, and 0.2% tergitol. After recording the
baseline, the sample was reduced with a few crystals of
dithionite, followed by CO bubbling for about one minute.
The CO spectrum difference of reduced microsomes was
measured on a Shimadzu UV-2101PC spectrophotometer
(Shimadzu Scientific Instruments Inc., Columbia, MD,
USA).
Interventional therapy with a cytochrome P-450 inhibitor.
Piperonyl butoxide (Aldrich Chemical Co., Milwaukee, WI,
USA), a cytochrome P-450 inhibitor, was administered
intraperitoneally in a dose of 400 mg/kg body wt twice at
48-hour intervals. The first injection was given 15 hours
prior to cisplatin injection. The effect of piperonyl butoxide
on the cytochrome P-450 content and bleomycin-detectable
iron in the kidney as well as renal functional and histolog-
ical changes subjected to cisplatin injection was evaluated.
In vitro study
Cell culture. LLC-PK1 cells (renal proximal tubular epi-
thelial cells) purchased from American Type Culture Col-
lection (CRL 1392; Rockville, MD, USA) were maintained
in Medium 199 supplemented with 3% fetal bovine serum
and penicillin (100 U/ml) in a humidified atmosphere of
95% air—5% CO2. The cells were maintained in 75 cm
2
tissue culture flask and the monolayer was subcultured
using 0.05% trypsin, 0.53 mM EDTA in calcium- and
magnesium-free Hank’s balanced salt solution (HBSS). For
the experiment, the cells were grown in a 6- or 12-well
tissue culture plate until confluency. All experiments were
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carried on confluent cell monolayer between passages 205
to 216.
Effect of cytochrome P-450 inhibitors on cisplatin-induced
cytotoxicity. LLC-PK1 cells were washed twice with HBSS
and then incubated in HBSS at 37°C with cytotoxic dose of
cisplatin for a period of time necessary to induce consistent
cytotoxicity (200 mg/ml for 4 hr) based on our previous
studies [10]. Two different inhibitors of cytochrome P-450
were used in the study. Cimetidine (2 mM; SmithKline
Beecham Pharmaceuticals, Philadelphia, PA, USA) or
piperonyl butoxide (1 mM) was added to the incubation
buffer 30 minutes prior to the addition of cisplatin and was
maintained throughout the incubation period. At the end
of incubation, the incubation buffer was collected and the
remaining cell monolayer was dissolved in 0.1% Triton
X-100. The lactate dehydrogenase (LDH) level in the
buffer and in the cellular fraction was measured by the use
of assay kit purchased from Sigma [10]. The degree of cell
injury was expressed as LDH release which is the percent-
age of LDH released into the buffer to total LDH recov-
ered from both buffer and cellular fraction.
Effect of cytochrome P-450 inhibitors on cisplatin-induced
catalytic iron release. LLC-PK1 cells were washed twice with
Chelex-treated HBSS and then incubated in Chelex-treated
HBSS with a cytotoxic dose of cisplatin for a period of time
before substantial cell killing occurred (200 mg/ml for 2.5
hr) [10]. Cimetidine (2 mM) or piperonyl butoxide (1 mM)
was added to the incubation buffer 30 minutes prior to the
addition of cisplatin. At the end of incubation, the incuba-
tion buffer was collected and the remaining cell monolayer
was dissolved in 0.2 N NaOH for the measurement of
cellular protein concentration by the use of Bio-Rad re-
agent. The catalytic iron released into the buffer was
measured by the bleomycin-detectable iron assay as de-
scribed and the results expressed as nmol/mg cellular
protein recovered from the cell monolayer.
Effect of a cytochrome P-450 inhibitor, cimetidine, on
platinum level. To exclude the possibility that cytochrome
P-450 inhibitors may interfere with cellular uptake of
Fig. 1. Effect of cytochrome P-450 inhibitor on cytochrome P-450 content
in both kidneys and liver of cisplatin-treated rats. Rats were given an
intraperitoneal injection of cisplatin (10 mg/kg body wt) and were
sacrificed at 72 hours after injection. A cytochrome P-450 inhibitor,
piperonyl butoxide (PB), was administered intraperitoneally twice in a
dose of 400 mg/kg body wt at 48-hour intervals. Values are means 6 SE.
The number of animals used was: control, N 5 5; cisplatin, N 5 9; PB,
N 5 9. *P , 0.01 compared with cisplatin treatment alone.
Fig. 2. Effect of cytochrome P-450 inhibitor on bleomycin-detectable iron
content in kidney of cisplatin-treated rats. Rats were given intraperitoneal
injection of cisplatin (10 mg/kg body wt) and were sacrificed at 72 hours
after injection. A cytochrome P-450 inhibitor, piperonyl butoxide (PB),
was administered intraperitoneally twice in a dose of 400 mg/kg body wt at
48-hour intervals. Values are means 6 SE, N 5 5. *P , 0.01 compared with
cisplatin treatment alone.
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platinum, LLC-PK1 cells were incubated with 200 mg/ml of
cisplatin in HBSS for four hours at 37°C in the absence or
presence of cimetidine (2 mM). At the end of experiment,
the cells were scraped and washed four times with phos-
phate-buffered saline. Then the cells were lysed in 100 ml of
water and sonicated. After centrifugation, the resulting
supernatants were used to measure platinum level by
atomic absorption spectroscopy with electrothermal atom-
ization [24]. The assay was performed by Dr. Thomas
Moyer in the Department of Laboratory Medicine and
Pathology at Mayo Clinic in Rochester, Minnesota.
Statistical analysis
Values are expressed as mean 6 standard error. Statis-
tical analyses were performed using unpaired Student’s
t-test (for only two groups) and analysis of variance (for
more than two groups). Statistical significance was consid-
ered at P value , 0.05.
RESULTS
In an in vivo study administration of cisplatin at a dose of
10 mg/kg body wt resulted in acute renal failure similar to
our previous studies [10]. At 72 hours after cisplatin
injection, BUN was significantly increased from 26 6 1
(N 5 5) to 109 6 6 mg/dl (N 5 9, P , 0.01) and plasma
creatinine increased from 0.69 6 0.05 (N 5 5) to 2.58 6
0.19 mg/dl (N 5 9, P , 0.01), respectively. Catalytic iron
content, as measured by the bleomycin-detectable iron
assay, was significantly increased from a control value of
0.85 6 0.06 to 1.70 6 0.09 nmol/mg protein (N 5 5, P ,
0.01) in the kidney of rats treated with cisplatin. To
determine whether cisplatin alters renal cytochrome P-450
content, we examined the cytochrome P-450 content in
cisplatin-induced acute renal failure. As shown in Figure 1,
there was a marked decrease in cytochrome P-450 content
(0.03 6 0.01 nmol/mg protein, N 5 9, P , 0.001) in the
kidney in cisplatin-treated rats compared to the control
animals (0.12 6 0.01 nmol/mg protein, N 5 5). The loss of
cytochrome P-450 content in the kidney was injury specific
because there was no difference in the level of cytochrome
P-450 content in the liver between the untreated and
cisplatin-treated animals (Fig. 1).
We postulated that the heme moiety of cytochrome
P-450 may serve as a significant source of catalytic iron in
cisplatin-induced nephrotoxicity. To test this hypothesis, we
examined the effect of a cytochrome P-450 inhibitor,
piperonyl butoxide (which yields a metabolite that binds to
the heme moiety of cytochrome P-450) [25] on the renal
content of cytochrome p-450 and catalytic iron in cisplatin-
induced acute renal failure. Piperonyl butoxide significantly
prevented the loss of cytochrome P-450 content in the
kidney of cisplatin-treated rats (Fig. 1). As a result of
preservation of cytochrome P-450 in the kidney, piperonyl
Fig. 3. Effect of cytochrome P-450 inhibitor on cisplatin-induced acute
renal failure as measured by blood urea nitrogen (A) and plasma
creatinine (B). Rats were given intraperitoneal injection of cisplatin (10
mg/kg body wt) and were sacrificed at 72 hours after injection. A
cytochrome P-450 inhibitor, piperonyl butoxide (PB), was administered
intraperitoneally twice in a dose of 400 mg/kg body wt at 48 hour intervals.
Values are means 6 SE. The number of animals used was: control, N 5 5;
cisplatin, N 5 9; PB, N 5 9. **P , 0.01 and *P , 0.05 compared with
cisplatin treatment alone.
Table 1. Semiquantitative analysis of renal tubule histology in rats
Group N
Histologic grade
0 I II III IV
Control 5 5
Cisplatin 5 2 3
1 Piperonyl butoxide 5 1 2 1 1
Five rats in each group were used for kidney histology study. Renal
function study in these subsets was not different from that in the overall
experimental groups. Renal tubule histologic grading is as follows: 0,
normal; I, areas of tubular epithelial cell swelling, vacuolar deneneration,
necrosis, and desquamation involving , 25% of cortical tubules; II, similar
changes involving . 25% but , 50%; III, similar changes involving . 50%
, 75% of cortical tubules; IV, similar changes involving . 75%.
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Fig. 4. Light-microscopy section of kidney. (A)
Control rat showing no abnormalities. (B) Rat
treated with cisplatin showing extensive
epithelial cell vacuolization, swelling,
desquamation and necrosis (grade IV)
occurring predominantly in the proximal
convoluted tubules. (C) Rat treated with a
cytochrome P-450 inhibitor, piperonyl butoxide,
showing a marked reduction in the extent of
tubular damage (grade I).
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butoxide also significantly blocked the increase in bleomy-
cin-detectable iron content in the kidney of animals treated
with cisplatin (Fig. 2). We then examined the effect of
piperonyl butoxide on renal functional and histological
change subjected to cisplatin treatment. Piperonyl butoxide
provided a marked protection against cisplatin-induced
acute renal failure as measured by BUN and creatinine
(Fig. 3). For histology study, we obtained five rats from
each group (control, cisplatin alone, cisplatin 1 piperonyl
butoxide). Renal function studies in these subsets were not
different from the overall experimental groups. The histo-
logical changes graded as described in the methods were
summarized in Table 1. As compared to control rats (Fig.
4A), cisplatin-treated rats had extensive epithelial cell
vacuolization, swelling, desquamation and necrosis (grade
IV) occurring predominantly in the proximal convoluted
tubules (Fig. 4B). There was a marked reduction in the
extent of tubular damage (grade I) in those animals treated
with piperonyl butoxide (Fig. 4C).
We also examined the role of cytochrome P-450 in an in
vitro model of cisplatin-induced cytotoxicity to LLC-PK1
cells. We used two different inhibitors of cytochrome
P-450, cimetidine and piperonyl butoxide, to increase the
specificity of our observation. Cimetidine has imidazole
and cyano groups that inhibit cytochrome P-450 by inter-
acting with the heme moiety [26]. This effect of cimetidine
is specific for cytochrome P-450 as it does not interact with
other heme enzymes [27]. Exposure to cisplatin led to a
significant increase in catalytic iron release from LLC-PK1
cells as measured by the bleomycin-detectable iron assay
(Fig. 5). Both inhibitors, cimetidine and piperonyl butox-
ide, significantly prevented the bleomycin-detectable iron
release from LLC-PK1 cells subjected to cisplatin treatment
(Fig. 5). Cimetidine and piperonyl butoxide also markedly
reduced cisplatin-induced cytotoxicity to LLC-PK1 cells as
measured by LDH release (Fig. 6). The cytochrome P-450
inhibitor, cimetidine, did not affect the cellular uptake of
cisplatin (data not shown). Taken together, our data
strongly suggest a role for cytochrome P-450, a group of
heme proteins, as a significant source of catalytic iron in
cisplatin-induced nephrotoxicity.
DISCUSSION
Despite compelling evidence for the role of iron in
various forms of tissue injury, the source of iron available to
participate in the generation of hydroxyl radical or other
iron-oxygen species remains largely unknown. In vivo most
of the iron is bound to heme and nonheme proteins and
does not directly catalyze the generation of hydroxyl radical
[1]. Based on the observation that hydrogen peroxide and
organic hydroperoxides can oxidatively degrade hemoglo-
bin and promote the release of iron from the heme chelate
[25], recent studies have demonstrated that cytochrome
P-450 serves as a potential source of catalytic iron in several
in vivo and in vitro models of myoglobinuric [9] and
ischemia/reperfusion-induced acute renal failure [18].
In our recent study [10], we have demonstrated that
the catalytic iron as measured by the bleomycin-detect-
able iron assay was significantly increased in LLC-PK1
cells exposed to cisplatin and in the kidney of rats treated
with cisplatin. Treatment with both iron chelators and
hydroxyl radical scavengers substantially prevented cis-
platin-induced cytotoxicity in vitro and acute renal failure
in vivo. Taken together, these data suggest a critical role
for iron in hydroxyl radical mediated cisplatin-induced
nephrotoxicity.
However, the role of cytochrome P-450 as a source of
catalytic iron in cisplatin-induced nephrotoxicity has not
Fig. 5. Effect of cytochrome P-450 inhibitors on bleomycin-detectable
iron release from LLC-PK1 cells exposed to cisplatin. Cells were incu-
bated with a cytotoxic dose of cisplatin (200 mg/ml) for a period of time
before substantial cell killing occurred (2.5 hr) in the presence or absence
of cytochrome P-450 inhibitors, cimetidine (2 mM) and piperonyl butoxide
(1 mM). Values are means 6 SE, N 5 3. * P , 0.01, compared with
cisplatin alone. Abbreviations are: Con, control; Cis, cisplatin; CM,
cimetidine; PB, piperonyl butoxide.
Fig. 6. Effect of cytochrome P-450 inhibitors on cisplatin-induced cyto-
toxicity to LLC-PK1 cells as measured by LDH release. Cells were
incubated with a cytotoxic dose of cisplatin (200 mg/ml) for a period of
time necessary to induce consistent cytotoxicity (4 hr) in the presence or
absence of cytochrome P-450 inhibitors, cimetidine (2 mM) and piperonyl
butoxide (1 mM). Values are means 6 SE N 5 4. *P , 0.01 compared with
cisplatin alone. Abbreviations are: Con, control; Cis, cisplatin; CM,
cimetidine; PB, piperonyl butoxide.
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been examined previously. In the present study, we have
demonstrated that the treatment with cisplatin resulted in a
significant increase of catalytic iron content accompanied
by decreased cytochrome P-450 content in the kidney. The
loss of cytochrome P-450 in the kidney induced by cisplatin
appears to be injury specific, because there is no difference
in cytochrome P-450 content in the liver between the
untreated and cisplatin-treated rats. The cytochrome P-450
inhibitor, piperonyl butoxide, prevented cisplatin-induced
loss of cytochrome P-450 and the increase of the bleomy-
cin-detectable iron in the kidney. Similarly, piperonyl bu-
toxide provided marked functional and histological protec-
tion against cisplatin-induced acute renal failure. In in vitro
studies using LLC-PK1 cells, the cytochrome P-450 inhibi-
tors, cimetidine and piperonyl butoxide, also provided
significant protection against cisplatin-induced increase in
catalytic iron content and cytotoxicity. The cytochrome
P-450 inhibitor, cimetidine, did not affect the cellular
uptake of cisplatin (data not shown). Taken together, our
data strongly suggest a role for cytochrome P-450, a group
of heme proteins, as a significant source of catalytic iron
capable of catalyzing free radical reactions in cisplatin-
induced nephrotoxicity. However, our study does not ex-
clude other roles of cytochrome P-450 in this model of
renal injury.
In a model of cisplatin nephrotoxicity, reactive oxygen
metabolites have been implicated [10, 15, 16, 19] and
increased release of endogenous heme have been demon-
strated [16]. It is very likely that oxidative stress could have
directly attacked the heme moiety of the cytochrome P-450
promoting the release of heme from its binding protein.
The inhibitors of cytochrome P-450 utilized in our study
may have stabilized and protected the cytochrome P-450
enzymes, thereby decreasing the destruction of the heme
chelate and the release of its iron. This is indicated by the
marked protection against cisplatin-induced loss of cyto-
chrome P-450 content in the kidney, and cytotoxicity af-
forded by the cytochrome P-450 inhibitors both in vivo and
in vitro associated with a significant decrease in the bleo-
mycin detectable iron.
The combination of cimetidine and verapamil has
been tested in a limited number of patients treated with
cisplatin [28]. This co-administration has been shown to
exert a beneficial effect on renal hemodynamics and has
been able to prevent the decrease in renal function that
normally occurs with cisplatin chemotherapy. Verapamil
by itself has been shown to have no significant effect in a
rat model of cisplatin-induced nephrotoxicity [20]. Our
results have shown that the cytochrome P-450 inhibitors
afford the beneficial effect on cisplatin-induced nephro-
toxicity. Thus, our observations may have obvious clinical
implications in future studies with cytochrome P-450
inhibitors playing a protective role against cisplatin-
induced nephrotoxicity.
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